Jul 27, 2026 06:32AM
Jul 27, 2026 06:32AM
Jul 14, 2026 07:02AM
Jul 3, 2026 07:30AM
Jun 11, 2026 08:03AM
Jun 11, 2026 08:02AM
Jun 5, 2026 07:30AM Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 3, 2026 06:55AM
Jun 3, 2026 06:53AM
Jun 2, 2026 08:33AM
Jun 2, 2026 08:32AM
May 26, 2026 06:02AM
May 26, 2026 06:02AM
May 19, 2026 04:02PM Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit
May 12, 2026 04:02PM
May 12, 2026 09:40AM
May 12, 2026 09:40AM
May 6, 2026 07:30AM
May 5, 2026 07:30AM
May 4, 2026 07:30AM
Apr 24, 2026 08:00AM Kyowa Kirin begins phase 2 trial of ziftomenib in Japan for AML
Apr 17, 2026 06:00AM
Apr 17, 2026 06:00AM
Apr 9, 2026 07:30AM
Apr 3, 2026 07:30AM
Mar 6, 2026 07:30AM
Mar 5, 2026 06:31AM
Feb 26, 2026 07:30AM Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results
Feb 25, 2026 07:30AM
Feb 6, 2026 07:30AM
Jan 12, 2026 04:07AM
Jan 11, 2026 05:00PM
Jan 5, 2026 07:30AM
Dec 8, 2025 10:30AM
Dec 8, 2025 10:30AM Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
Dec 3, 2025 08:32AM
Dec 2, 2025 08:02AM
Dec 2, 2025 08:02AM
Nov 25, 2025 05:19PM
Nov 25, 2025 05:16PM
Nov 20, 2025 04:02AM
Nov 13, 2025 10:51AM FDA approves KOMZIFTI for relapsed NPM1-mutated acute myeloid leukemia
Nov 13, 2025 10:51AM
Nov 13, 2025 10:15AM
Nov 4, 2025 06:31AM
Oct 1, 2025 07:01AM
Oct 1, 2025 07:01AM
Sep 30, 2025 06:52AM
Sep 29, 2025 04:01PM Kura Oncology and Kyowa Kirin dose first patient in phase 3 AML trial
Sep 29, 2025 04:01PM

326,527 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All